Anti-HER2 antibody enhances the growth inhibitory effect of anti-oestrogen on breast cancer cells expressing both oestrogen receptors and HER2
2000
Combining Anti-HER2 Antibody and Anti-Oestrogen for Breast Cancer Treatment
publication
Author Information
Author(s): Kunisue H, Kurebayashi J, Otsuki T, Tang C K, Kurosumi M, Yamamoto S, Tanaka K, Doihara H, Shimizu N, Sonoo H
Primary Institution: Kawasaki Medical School
Hypothesis
Combined therapy with anti-oestrogen and anti-HER2 antibody might be more effective for treating breast cancer.
Conclusion
The study suggests that combined treatment with anti-HER2 antibody and anti-oestrogen may be useful for patients with breast cancer expressing both ER and HER2.
Supporting Evidence
- The combined treatment enhanced the growth inhibitory effect on ML-20 cells.
- No additive effect was observed on KPL-4 and MDA-MB-231 cells.
- Both the antibody and anti-oestrogen induce a G1–S blockade and apoptosis.
Takeaway
Using two types of medicine together can help fight certain breast cancers better than using just one.
Methodology
The study investigated the effects of combined treatment with trastuzumab and ICI 182,780 on three human breast cancer cell lines.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website